Abstract: Methods and pharmaceutical compositions for treating neurodegeneration in patients diagnosed with Parkinson's Disease. Intranasal therapeutic agents, e.g., chelators, are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal systemic side effects. Therapeutic agents include those substances that interact with iron and/or copper such as metal chelators generally, including but not limited to iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO).

Abstract: A method, system, and computer program product for amorphous data preparation for intelligent data source selection in application development are provided in the illustrative embodiments. A set of keywords is selected from a code portion of a source code. Using a subset of the set of keywords, an expected circumstance is determined, the expected circumstance being a circumstance relevant to a purpose of the source code. From a set of data sources, a data source is identified, wherein the data source provides information usable in the expected circumstance. A manner of accessing the information from the data source is identified. Pseudo-code is constructed to implement the manner of accessing the information from the data source. A weight is assigned to the data source based upon a type of input used for selecting the pseudo-code, wherein the selecting uses the pseudo-code in the source code.

Abstract: A method, system, and computer program product for amorphous data preparation for intelligent data source selection in application development are provided in the illustrative embodiments. A set of keywords is selected from a code portion of a source code. Using a subset of the set of keywords, an expected circumstance is determined, the expected circumstance being a circumstance relevant to a purpose of the source code. From a set of data sources, a data source is identified, wherein the data source provides information usable in the expected circumstance. A manner of accessing the information from the data source is identified. Pseudo-code is constructed to implement the manner of accessing the information from the data source. A weight is assigned to the data source based upon a type of input used for selecting the pseudo-code, wherein the selecting uses the pseudo-code in the source code.

Abstract: Described herein are systems and methods for automatically selecting a content provider for delivery of content for consumption by a user. Various selection data such as cost, historical delivery bitrate, and so forth are gathered and a weighting profile is applied to generate a total weight by content provider. The total weight by content provider may be used to select one content provider from another for delivery of a particular piece of content.

Abstract: A method, computer program product and system for generating and maintaining synthetic context events. The steps include searching a data structure of synthetic context-based objects and associated data for a pattern of context exhibited at a first specified frequency within a first specified time period; combining the synthetic context-based objects and associated data exhibiting the pattern of context exhibited at the first specified frequency within the first specified time period into a synthetic context event; and optimizing and maintaining the synthetic context event by searching the data structure for additional synthetic context-based objects and associated data exhibiting a same pattern of context at a second specified time period different than the first specified time period and adding the additional synthetic context-based objects and associated data to the synthetic context event.

Abstract: A method, system, and computer program product for detecting anomalous events from a data input comprising a plurality of events. The method comprising the steps of: selecting at least one filter selecting for context data determined to be probabilistically present within a specified degree of certainty in the data input; comparing the data input to the selected at least one filter; discarding the events from the data input that are the same as the context data for which the at least one filter selects; and storing in a repository the events remaining in the data input as anomalous events.

Abstract: A method, system and computer program product for maximizing the utility of data obtained from multiple intersecting data structures and stored in a multi-dimension information space. The method includes the steps of generating a rigid mathematical structure within the multi-dimensional information space; dividing the rigid mathematical structure into segments, each segment having a volume determined by a time of access to the segment relative to an event, a duration of access to the segment and a quantity of data in the segment; and determining a sellable price point for each segment of the rigid mathematical structure based on the volume of the segment.

Abstract: The gasification of a carbonaceous material includes receiving a volume of feedstock, supplying thermal energy to the volume of feedstock to convert at least a portion of the volume of feedstock to at least one pyrolysis reaction product via at least one pyrolysis reaction, super-heating the at least one pyrolysis reaction product, providing a volume of super-heated steam, mixing the volume of super-heated steam with the super-heated at least one pyrolysis reaction product and converting at least a portion of at least one reformed product to at least one synthesis gas product via at least one water-gas-shift reaction.

Abstract: Methods for treating the animal central nervous system against the effects of stoke, including associated cognitive, behavioral and physical impairments. Effective amounts of therapeutic agents are administered to the upper third of the stroke patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO).

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of cerebral hemorrhage and subarachnoid hemorrhage. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, cerebral hemorrhage and subarachnoid hemorrhage. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the cerebral hemorrhage and subarachnoid hemorrhage.

Abstract: Methods for treating the animal central nervous system against the effects of spinal cord injury, including associated cognitive, behavioral and physical impairments. Effective amounts of therapeutic agents are administered to the upper third of the patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO).

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Lewy body syndrome. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, Lewy body syndrome. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the Lewy body syndrome.

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of stoke, including associated cognitive, behavioral and physical impairments. Initially, a patient at risk for stroke is identified. Effective amounts of therapeutic agents are administered to the upper third of the at-risk patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO).

Abstract: Methods for treating the animal central nervous system for the effects of traumatic brain injury. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient suffering from traumatic brain injury. The effective amount of DFO is delivered directly to the patient's central nervous system for treating the traumatic brain injury.

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of progressive supranuclear palsy. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, progressive supranuclear palsy. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the progressive supranuclear palsy.

Abstract: Methods for preconditioning, treating and/or providing neuroprotection to the animal central nervous system against the effects of neurodegeneration caused by iron accumulation in the brain. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. An examplary therapeutic agent is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for or diagnosed with neurodegeneration caused by iron accumulation in the brain. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating neurodegeneration caused by iron accumulation in the brain.

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Huntington's disease. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with Huntington's disease. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating Huntingon's disease.

Abstract: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1? (HIF-1?). HIF-1? is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized.

Abstract: Methods and pharmaceutical compositions for providing neuroprotection to the animal central nervous system against the effects of ischemia, and neurodegeneration. Patients at risk for certain diseases or disorders that are associated with cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators and copper chelators. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO).

Abstract: Pharmaceutical compositions for treating and/or pre-treating or preconditioning the animal central nervous system against the effects of Alzheimer's Disease including the associated neurodegeneration and cognitive, behavioral and physical impairments. In one embodiment, an effective dose of deferoxamine (DFO) is administered to the upper one-third of the subject patient's nasal cavity to effectively bypass the blood-brain barrier, thereby allowing application of the DFO dose directly to the central nervous system.